IN THE CLAIMS

Please amend claims 1 and 5 as follows:

1. (Currently Amended) A method of identifying a candidate psychiatric patient for treatment with ~~atypical~~ antipsychotic or antidepressant medication that acts at a D2 dopamine receptor (DRD2) or influences D2 dopamine receptor density, the method comprising:

determining whether the patient's DRD2 genotype is Taq1A allele positive (A1+) or Taq1A allele negative (A1-); wherein:

an A1+ genotype is indicative of a candidate for treatment with ~~high dose high~~ low dose DRD2 binding ~~atypical~~ antipsychotics and/or SSRIs ~~that increase D2 dopamine receptor density~~; and

an A1- genotype is indicative of a candidate for treatment with ~~low dose~~ high dose ~~or low~~ D2 dopamine receptor binding ~~atypical~~ antipsychotics or alternative antidepressant.

2. (Original) The method of claim 1, wherein the psychiatric patient suffers from schizophrenia.

3. (Original) The method of claim 1, wherein the patient suffers from post-traumatic stress disorder (PTSD), depression, social anxiety or mixed anxiety and depressive states.

4. (Original) The method of claim 1, wherein the patient suffers from Parkinson's disease.

5. (Currently Amended) The method of claim 1, wherein the ~~high~~ DRD2 binding ~~atypical~~ antipsychotic is risperidone.

6. (Previously Presented) The method of claim 1, wherein the SSRI is paroxetine.